Using aspirin to prevent heart problems in women with preeclampsia
Aspirin to prevent cardiac dysfunction in preeclampsia
This study is looking at whether taking aspirin can help improve heart health and lower a certain growth factor in women with preeclampsia, a pregnancy condition that can lead to serious heart issues after giving birth.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11001099 on NIH RePORTER |
What this research studies
This research investigates the potential of aspirin to improve heart function and reduce the levels of a specific growth factor, Activin A, in women diagnosed with preeclampsia. Preeclampsia is a serious condition that can lead to high blood pressure and organ damage during pregnancy, increasing the risk of heart failure after childbirth. The study involves a randomized trial where participants will receive either aspirin or a placebo, alongside investigations into how these treatments affect heart health and the role of Activin A. By understanding these mechanisms, the research aims to develop effective strategies to prevent heart complications in postpartum women.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant women diagnosed with preeclampsia during their second trimester.
Not a fit: Patients who are not pregnant or those without a diagnosis of preeclampsia are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new preventive treatments for heart dysfunction in women who experience preeclampsia.
How similar studies have performed: Previous research has shown promising results in using aspirin for various pregnancy-related complications, but this specific approach to prevent cardiac dysfunction in preeclampsia is relatively novel.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Shahul, Sajid — University of Chicago
- Study coordinator: Shahul, Sajid
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.